
Maximilian Merz
Articles
-
Dec 8, 2024 |
fnweb.de | Maximilian Merz
Die Merlins Crailsheim haben in der 2. Basketball-Bundesliga „Pro A“ gegen Rasta Vechta II nach zuletzt drei Heimniederlagen verdient mit 95:69 gewonnen. Der erste Durchgang gehörte dabei eindeutig den „Zauberern“, die sich angeführt von Vize-Kapitän Vinnie Shahid über 20 Minuten absetzten. Die Crailsheimer Überlegenheit des ersten Durchgangs setzte sich auch in den zweiten 20 Minuten weiter durch und endete in einem erlösenden Heimsieg.
-
Dec 4, 2024 |
nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Dec 4, 2024 |
nature.com | Sarah Flossdorf |Sandra Sauer |Hartmut Goldschmidt |Monika Engelhardt |Robert Zeiser |Vladan Vucinic | +5 more
AbstractIdentifying patients who may benefit from autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma is crucial, especially in the era of effective induction and consolidation strategies. We analyzed data from 12763 patients enrolled in the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST), distinguishing those who underwent single (n = 8736) or tandem ASCT (n = 4027) from 1998 to 2021.
-
Dec 4, 2024 |
nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Aug 26, 2024 |
nature.com | Maximilian Merz
Early trials of immune checkpoint inhibitors (ICIs) in multiple myeloma (MM) showed increased mortality, halting their development. A study now reports promising results and distinct changes in the immune microenvironment after TIGIT and LAG3 blockade in heavily pre-treated patients with MM, marking a potential revival for ICIs in MM therapy.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →